PHAXIAM Therapeutics S.A. (PHXM)

PHAXIAM Therapeutics Cash Flow Statement

Financials in millions EUR. Fiscal year is January - December.

Year	2022	2021	2020	2019	2018	2017	2016	2015
Net Income	-0.23	-53.8	-73.3	-62.66	-38.22	-33.53	-21.91	-15.01
Depreciation & Amortization	4.62	5.38	4.99	4.22	0.8	0.53	0.43	0.29
Share-Based Compensation	0.45	1.32	1.18	1.36	2.45	1.77	1.18	2.72
Other Operating Activities	-36.6	-9.67	15.41	13.77	-12.88	6.53	2.7	-2.57
Operating Cash Flow	-31.76	-56.77	-51.72	-43.31	-47.86	-24.7	-17.61	-14.58
Capital Expenditures	37.55	-0.3	-1.06	-20.12	-5.64	-1.66	-1.75	-0.27
Change in Investments	0.59	0.15	0	0.41	0	0	-0.04	-0.02
Other Investing Activities	-0	-0.19	-0.42	-0.14	-0.82	-0.13	-	-
Investing Cash Flow	38.13	-0.35	-1.48	-19.84	-6.45	-1.79	-1.79	-0.28
Share Issuance / Repurchase	0	34.63	0.13	0.05	0	177.58	9.24	23.61
Debt Issued / Paid	-1.55	10.46	25.46	-1.72	-0.82	-0.03	2.15	-0.09
Other Financing Activities	-0.22	-0.37	-0.14	1.71	-	-	-	0
Financing Cash Flow	-1.77	44.71	25.45	0.04	-0.82	177.55	11.39	23.52
Exchange Rate Effect	0.5	1.66	-0.98	1.91	3.98	-3.18	0.02	-0.02
Net Cash Flow	5.09	-10.75	-28.73	-61.2	-51.14	147.87	-7.99	8.65
Free Cash Flow	5.78	-57.07	-52.78	-63.43	-53.49	-26.37	-19.37	-14.85
Free Cash Flow Margin	18.65%	-1365.26%	-1419.47%	-1200.59%	-1202.88%	-783.77%	-467.98%	-506.90%
Free Cash Flow Per Share	1.86	-21.59	-29.42	-35.35	-29.82	-15.45	-11.35	-

Source: Financials are provided by Nasdaq Data Link and sourced from audited reports submitted to the Securities and Exchange Commission (SEC).